Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
And four other potential targets that could make sense for the beleaguered group.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.